Deutsche Bank analyst Esther Rajavelu recently met with two compounding pharmacists to assess their ability and motivation to switch patients to TX-001, TherapeuticsMD's single pill combination for vasomotor symptoms in menopausal women. The analyst remains optimistic over "strong uptake in this patient segment." The company's opportunity from compounded hormone therapies to TX-001 remains underappreciated, Rajavelu tells investors in a research note. The analyst models launch in late 2018 with revenue reaching $1B in five years. Rajavelu reiterates a Buy rating on the shares with a $10 price target.